story of the week
Adjuvant Tamoxifen Provides a Survival Benefit Over No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 Years) of the Phase III SBII:2pre Trial
J. Clin. Oncol 2016 May 09;[EPub Ahead of Print], M Ekholm, PO Bendahl, M Fernö, B Nordenskjöld, O Stål, L RydénFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.